Brief: Transgene: Positive Interim Results Phase II Trial For TG4001 + Avelumab Versus Avelumab In HPV-Positive Anogenital Cancers

Transgene SA

02/11/2022 16:51

Nov 2 (Reuters) - Transgene Sa  TRNG.PA :
    * TRANSGENE ANNOUNCES POSITIVE INTERIM ANALYSIS RESULTS OF
PHASE
II TRIAL EVALUATING TG4001 + AVELUMAB VERSUS AVELUMAB IN
HPV-POSITIVE ANOGENITAL CANCERS
    * BASED ON POSITIVE SIGNALS OBSERVED IN INTERIM ANALYSIS,
TRIAL IS
NOW EXPECTED TO ENROLL AN ADDITIONAL 66 PATIENTS
    * TRANSGENE ANTICIPATES LAST PATIENT TO BE RANDOMIZED IN
TRIAL IN
H1 2024

Source text for Eikon:  ID:nBwg2RM9a 
Further company coverage:  TRNG.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))